|
Synonyms: ALD-518 | ALD518 | BMS-945429
Compound class:
Antibody
Comment: Clazakizumab is an investigational, aglycosylated, humanized (from a rabbit parental antibody) monoclonal antibody targeting interleukin-6, with anti-inflammatory potential [2].
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. BLAST peptide sequence analysis reveals identical matches with peptides claimed in patent US8062864 [3]. Results presented in the patent show that the preferred antibodies block interaction of IL-6 with the IL-6 receptor, but no precise binding affinity data is provided. |
| No information available. |
Summary of Clinical Use  |
| Phase 2 clinical trials in patients with active rheumatoid arthritis (NCT01373151, results reported in [6]), psoriatic arthritis (NCT01490450, results in [5]), cachexia resulting from non-small cell lung cancer [1,4], acute graft versus host disease (GvHD) and oral mucositis caused by head and neck cancer have been completed. Click here to link to ClinicalTrials.gov's list of clazakizumab (ALD518 and BMS-945429) trials. SARS-CoV-2 and COVID-19: Clazakizumab has been entered into clinical trials in patients with COVID-19, with a particular focus on assessing its efficacy in those with life-threatening hyperinflammation. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01373151 | Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate | Phase 2 Interventional | Vitaeris INC | ||
| NCT01490450 | Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy | Phase 2 Interventional | Vitaeris INC | ||
| NCT04381052 | Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection | Phase 2 Interventional | Columbia University | ||
| NCT04363502 | Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection | Phase 2 Interventional | Johns Hopkins University | ||
| NCT04351724 | Austrian CoronaVirus Adaptive Clinical Trial (COVID-19) | Phase 2/Phase 3 Interventional | Medical University of Vienna | ||
| NCT04348500 | Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease | Phase 2 Interventional | Cedars-Sinai Medical Center | ||
| NCT04343989 | A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection | Phase 2 Interventional | NYU Langone Health | ||
